EVLO - Seres Therapeutics at a four-month high after update on study for microbiome drug

The shares of Seres Therapeutics (MCRB +18.6%) have reached the highest level in more than four months after the company announced the enrollment of the first patient in an early-stage study for microbiome therapy SER-155 in graft-versus-host disease ((GvHD)). Conducted in partnership with Memorial Sloan Kettering Cancer Center and The University of Chicago, the Phase 1b study is designed to test the investigational drug among approximately 70 adult patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). The company has sole global rights for SER-155, an oral collection of cultivated bacteria. Other companies focused on microbiome-based therapeutics include Evelo Biosciences (EVLO +2.7%), Finch Therapeutics (FNCH +1.0%), Evogene (EVGN -2.9%), and Kaleido Biosciences (KLDO -5.9%). Compared to peers, Seres (NASDAQ:MCRB) has dropped the most in value in the year so far, as shown in the graph below.

For further details see:

Seres Therapeutics at a four-month high after update on study for microbiome drug